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determined that the payment amount will be segmented calculated. Besides, com-
mercial companies are responsible to provide insurance. Thus the article sum-
marizes and compares the financing level, deductible and cap lines. Results: 18 
provinces determined the financing level: 11 provinces were from 10 CNY to 60 
CNY per capita annually; the rest equaled 5% to 10% of BMI premium. 22 provinces 
determined deductible: 15 provinces calculated deductible based on urban per 
capita disposable income (or rural per capita net income). 7 provinces determined 
cap line: 4 provinces were from 200 000 CNY to 400 000 CNY and the rest were no 
cap. ConClusions: 1. In all related provinces, the financing level is relatively low, 
while segmented calculation and the cap line lead to high payment. The main chal-
lenge is how to balance the income and expenditure of the insurance. 2. Since the 
central government did not define what critical illness insurance can reimburse, 
some provincial governments strictly control the range. In some other provincial 
governments, like Anhui, the range of the insurance is too wide. However, consid-
ering the insurer is commercial companies, the gaming between companies and 
governments will continue.
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accEss ProcEss?
Clay E.1, Yan J.2, Chen C.3, Toumi M.4
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, London, UK, 3Bayer HealthCare, Beijing, China, 
4University of Marseille, Marseille, France
objeCtives: China is the third largest pharmaceutical market in the world. The 
aim of this study was to describe Chinese reimbursement process, assess current 
policies and provide the authors’view of Europeans difficulties to understand the 
Chinese market access. Methods: A review was done using the latest-released 
official documents published by January 2014, to collect information regarding 
Chinese health care reimbursement pathways with the perspective of market 
access. Information was analysed based on authors’expertise, summarising the 
general pathway, and comparing with European routine. Results: Three stake-
holders participate in Chinese market access process: Ministry of Health (MoH) 
(supporting introduction of new health care technologies), National Development 
and Reform Commission (referencing prices based on technical information), and 
Bureau of Human Resources and Social Security (representing budget holders; focus-
ing on cost containment). Differences between Chinese process and European rou-
tine result in European hardly understanding Chinese market access process: 1> in 
China, key opinion leaders introduce the dossier whereas in Europe, companies 
introduce the dossier. 2> in China, completely new health care technologies need 
real life pilot studies (RLPS) pre-requisitely to address the feasibility and impact of 
introduction, whereas in Europe, RLPS studies are requested after a granted market 
access. 3> in China, reimbursements start from regional level as pilot in 3 regions 
before becoming national whereas in Europe they start from national before regional 
contact. 4> in China, the three stakeholders negotiate internally reimbursements, 
prices and access conditions, whereas in Europe, companies negotiate with pay-
ers. 5> Chinese MoH has an envelope for direct funding of health care technologies 
through procurement, whereas no comparable envelope held by similar stakehold-
ers in Europe. ConClusions: Chinese market access is difficult for European to 
understand because of fundamental differences in the paradigm sustaining pricing 
and reimbursement (P&R). Clarifying the rational for the differences in paradigm is 
a prerequisite for European understanding of the P&R in China.
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objeCtives: The objective of this study was to develop a patient centred model 
which can be used by clinicians for each patient. Methods: Two hypothetical, but 
realistic, treatments were selected to demonstrate the value of this model, a “mod-
ern atypical drug” and a “typical drug”. The “modern atypical drug” is more expen-
sive, results in faster return to work, less days in hospital and fewer repeat visits 
than the “typical drug”. The computer based model provides default differences on 
all of these variables, however, the end user can over write these to allow the cost 
off-sets to be individualised to each patient they are treating. Results: While the 
“modern atypical drug” is more expensive on a per day basis ($4.00 vs $0.30), days 
of treatment can be shorter, hospital stay and doctor visits reduced and days off 
work lower, making it a less expensive treatment option overall. In the base case, 
the medication cost of the “modern atypical drug” was $108 more expensive over 
the year of treatment ($4 per day x 30 days versus $0.30 per day x 40 days). Shorter 
length of stay (3 versus 10 days at $50 per day) resulted in $350 in savings. Modest 
savings were gained from fewer doctor visits. Substantial savings would be expected 
from fewer days off work (14 versus 45 days off work at $100 per day) with around 
$3,100 saved. Overall savings were $3,432. This model could be adjusted to reflect the 
expected outcome for each patient. ConClusions: This is exercise demonstrates a 
novel model design which allows doctors to assess individual patients to determine 
whether or not they should be considered for more expensive treatments. It is well 
suited to health care environments in the region.
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objeCtives: Risk sharing agreements (RSA) are sometimes used to offset the risk 
associated with any uncertainties which may surround a drug at the time of launch. 
They can offer payers and manufactures the flexibility to manage some of the per-
ceived risks associated with, but not limited to, high therapy costs, discretionary 
use within an unapproved patient population, or lack of data at the time of product 
assessment. Given the frequent implementation of RSAs in Australia, the aim of 
aged 39 days (17 days for oncology and 14 days for orphan drugs). Across the EU5, 
Germany was fastest while Italy was slowest (16 vs. 66 weeks). Other factors con-
sidered included: UK reimbursement decisions by SMC and NICE often lengthened 
time to access; Germany: Time to market has increased by ~8 weeks since the 2011 
introduction of AMNOG; Italy and France have special license programs which can 
shorten time to market for products addressing unique needs or populations; and 
In Spain commercialization of orphan and oncology drugs takes longer than general 
medications. ConClusions: Average time to market in the US vs. EU5 countries 
is considerably different. In the EU5, the German and UK launch on average were 
within 4 to 6 months of authorization; Italy was greater than a year. Launch times 
for orphan and oncology drugs also differ based on priorities set within health sys-
tems. Differences in country and product type have led to different market access 
timelines and regulatory changes will only increase these disparities.
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objeCtives: To describe policies of drug cost sharing in health insurance schemes 
and how the authors have assessed the effects where available. Methods: A sys-
tematic review was conducted in 2009 and updated in 2013. Results: Totally 28 
studies were included. 1) Some insurance schemes introduced a new drug cost 
sharing program, the increase rates of total number of prescriptions were smaller 
compared with the non cost-sharing group; At the same time, prescription drug cost 
sharing also decreased use of essential drugs or adherence to medications which 
induced adverse effects on vulnerable population such as the poor, the elderly and 
patients with chronic diseases. Average prescription cost increase rate was lower 
in the cost sharing group than the non cost-sharing group. 2) For Different Tiers of 
Prescription Copayment System, there were some positive effects showing that the 
consumption of generic drugs increased in both single-tired and three-tiered groups, 
especially higher proportion in the three-tiered system. Higher levels of prescrip-
tion drug cost sharing actually decrease inappropriate drug use with a relatively 
inelastic price elasticity of demand. For the patients with chronic diseases such as 
heart failure or diabetes, lower adherence of medication followed by higher copay-
ment would increase risk of hospitalization. Different levels of copayment could 
control moral hazard of the patients with decreased rates of switching to a relatively 
more expensive drug and an increased rate of switching to drugs of equal or lesser 
cost. 3) Increasing cost sharing level was followed by decreasing the utilization of 
prescription drugs and increasing in out of pocket especially for the vulnerable 
population. ConClusions: To increase or decrease the level of cost sharing could 
change the beneficiaries’ behavior, the vulnerable population were more sensitive 
than the general. Different levels of cost sharing method seem as one of the suc-
cessful tools to control moral hazard.
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objeCtives: The objective of this study was to identify key value drivers to achieve 
pricing premiums through the similar efficacy comparator pricing method for inno-
vative products in Japan. Methods: We analysed all products that were priced by 
the Central Social Insurance Medical Council (Chuikyo) using the similar efficacy 
comparator pricing method (I) from January 2010 to March 2014. Where relevant, the 
pricing premium and premium criteria met within each category were analysed in 
detail. Results: Of 102 products assessed, 36 products (35%) were granted pricing 
premiums, which ranged from 5-50%. The most common premium category 
was utility (69%), followed by paediatric use (19%) and marketability (17%). Four 
products fell into two categories and were granted both pricing premiums. Of the 
seven orphan drugs assessed, six gained a 10% marketability (I) premium, while 
one achieved marketability (II) with only a 5% premium, as the orphan indication 
was not its main indication. Paediatric-use premiums ranged from 5-10%, with 
higher premiums dependent on unmet need and availability of similar therapies. 
5-15% utility (II) premiums were achieved by products with improved MOA, efficacy, 
safety or therapeutic method. Only two products, fingolimod and telaprevir, were 
designated as utility (I) innovations, which qualified them for pricing premiums of 
35-60%. Fingolimod was the first oral therapy approved to treat relapsing forms of 
multiple sclerosis. Its novel MOA, improved administration and efficacy, as well as an 
orphan indication, secured fingolimod a 50% pricing premium. Similarly, telaprevir 
was also valued by Chuikyo for its novel MOA and significant clinical improvement 
over the standard of care, resulting in a 40% pricing premium. ConClusions: 
Clinical benefit and unmet need are the main value drivers for premium pricing 
in Japan. To achieve > 20% pricing premium, a product needs to meet at least two 
utility premium criteria to be categorized to utility (I).
PHP65
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anD ProsPEcts
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objeCtives: China has a complex system to provide basic medical insurance (BMI) 
for over 95% population. However 35% of the total medical expense is out-of-pocket. 
To relieve people’s burden, China implemented critical illness insurance from 2012. 
Critical illness insurance is based on BMI and aims to provide further protection for 
urban and rural unemployed residents. The article aims to summarize the plans 
of critical illness insurance from 24 provinces, to conclude the developments and 
prospects. Methods: The 24 plans were published from October 2012 to December 
2013. The participants of the insurance are urban and (or) rural residents. All plans 
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objeCtives: Evidence based medicine has been used for about two decades as 
methodology for obtaining, evaluating and presenting information on health 
related topics. The present study investigated the question of the appearance 
of the ideas of evidence based medicine in documents describing the function-
ing of European health care systems. Methods: The documents available in the 
European Observatory on Health Systems and Policies database were considered 
to reliable represent the health system of European countries. Structured text 
analysis was carried out according to previously described methodology. All evalu-
ation steps were carried out in parallel by two researchers (K.M. and Sz.L.). Two 
studies carried our previously on related topics were used to relate the results 
obtained in the present study with data of the literature. Results: The cumula-
tive length of the documents was 6449 pages; there was no document without 
mentioning the idea of evidence based medicine. Among the altogether 413 men-
tioning of evidence based medicine, we were able to categorise 208 representa-
tions of the idea into one of the following 4 topics: 1. resources of health care, 2. 
health technology assessment, 3. organisation of health care and 4. environment 
of health care within the society. Evidence based medicine was mentioned 57 
in connection with the resources of health care, whereas 31 mentioning were 
related to health technology assessment. Organisation of health care was men-
tioned together with evidence based medicine at 56 occasions, whereas the idea 
of evidence based medicine was related to the social environment of health care 
in 64 instances. ConClusions: The results of the present data collection indicate 
that the methodology of evidence based medicine has already been widely used 
within the documents describing health systems and policies in Europe. However, 
there were considerably differences in the extent and depth of applying evidence 
based medicine methodology.
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objeCtives: Pharmacoeconomics is the application of economics to assess 
pharmaceutical and health care products that helps evaluate economic, clinical 
and humanistic outcomes of health care products and interventions. It gives 
health care decision makers, providers and patients with valuable informa-
tion for optimal use and allocation of limited health care resources. In India, 
the awareness of pharmacoeconomics is relatively low among policy makers, 
academia and industry. As India’s pharmaceutical market changes and evolves, 
the study of pharmacoeconomics and associated research is expected to gain 
momentum. Methods: Secondary research was conducted using PubMed. 
Several search terms like “pharmacoeconomics”, “cost minimization”, “cost 
benefit”, “cost utility”, and “cost effectiveness” analysis were used. These terms 
were also used in different combinations, e.g., “Cost Minimization Analysis and 
Pharmacoeconomics and India”, “Cost Benefit Analysis and Pharmacoeconomics 
and India”, to extract relevant studies. No search term or time restrictions 
were applied while extracting studies. Results: Overall, a total of 228 stud-
ies were extracted using the search terms. “Pharmacoeconomics and India” 
yielded 192 results out of which only five studies were relevant to pharmaco-
economics in India. Search terms “Cost Minimization Analysis and India and 
Pharmacoeconomics” gave only two results. Fifteen results were obtained for 
the term “Cost Benefit Analysis and Pharmacoeconomics and India” out of 
which four studies were relevant to the objective. “Cost Utility Analysis and 
Pharmacoeconomics and India” resulted in four results out of which two were 
repetitions of results from “cost minimization analysis”. “Cost effectiveness 
analysis and pharmacoeconomics and India” resulted in 15 results; 10 in last 
10 years and only 2 were relevant. ConClusions: As seen from the results, not 
much pharmacoeconomic research has been conducted in India suggesing the 
dearth of literature in this area in India. As the Indian pharmaceutical market 
evolves and policies change, greater amount and rigorous pharmacoeconomics 
research may be needed.
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objeCtives: To explore the attitudes and perceptions of patient safety culture for 
health care workers in China by using a modified Hospital Survey on Patient Safety 
Culture (HSPSC) questionnaire. Methods: The survey measuring 10 dimensions 
of patient safety culture with 36 items was conducted from 32 hospitals in 15 cit-
ies all across China. We computed descriptive statistics and Chi-Square test was 
performed to explore the differences on the perception of patient safety culture 
in groups of different work units, positions and qualification levels. SPSS 17.0 was 
used to perform data extraction and analysis. Results: A total of 1500 question-
naires were distributed of which 1160 were responded validly (response rate 77%). 
Seven hundred and twenty two (66%) of the respondents were nurses, 386 (33%) 
were surgical clinicians and 343 (30%) were internal medicine clinicians. The posi-
tive response rate for the 10 patient safety culture dimensions ranged from 45% 
to 88%, the mean positive response rate was 65%. The lowest positive response 
rate of dimension was “Staffing” (45%), while the highest positive response rate of 
dimension was “Organization Learning-Continuous Improvement” (88%). The positive 
response rate of two dimensions of nurse was lower than that of physicians (“Overall 
Perceptions of Patient Safety” and “Communication Openness” P < 0.05). Furthermore, the 
positive response rate of physicians with high qualification (chief physicians) on 
two dimensions (“Overall Perception of Patient safety” and “Feedback & Communication 
About Errors” P < 0.05) was higher than those having a low qualification level (resi-
dents). ConClusions: The results show that amongst the health care workers 
surveyed in China there was a positive attitude towards the patient safety culture 
within their organizations.
this study was to assess the trends which drive risk sharing agreements with the 
Pharmaceutical Benefits Advisory Committee (PBAC) within a four month period in 
2013. Methods: All PBAC decisions from August to November 2013 were surveyed 
by looking at the general RSA structures outlined in the PBAC guidelines. The fol-
lowing data were extracted from each appraisal: assessment outcome (positive or 
negative), RSA consensus (yes or no), RSA type (rebate and recovery, price volume, 
data provision, shared deeds), therapeutic area, product price, product incremen-
tal cost-effectiveness ratio, market size, structure of trial, trial outcomes, and the 
availability of alternative therapies. Results: The analysis revealed that 44% of 
PBAC decisions incorporated some form of an RSA, and 91% of products with RSAs 
received a positive PBAC decision. The majority of RSAs were rebate recovery or price 
volume arrangements, where the PBAC was concerned with the product’s use in a 
larger-than-specified population. ConClusions: The results of this study indicate 
the PBAC readily enters into RSAs when doubt exists surrounding the potential cost 
or efficacy of a drug. Accurately identifying areas of product risk and proposing an 
RSA to address it can lead to a favourable decision from the PBAC.
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objeCtives: The objective of this study was to compare the Health Technology 
Assessment (HTA) timing and decisions for recently launched products in South 
Korea and Taiwan, and to provide insight into launch strategies in these mar-
kets. Methods: We analysed all products that were assessed for reimbursement 
by the Health Insurance Review & Assessment Service (HIRA) in Korea and by 
the National Health Insurance Administration (NHIA) and the Centre for Drug 
Evaluation (CDE) in Taiwan from January 2012 to March 2014. Where relevant, the 
details of the assessments have been extracted from the NHIA meeting minutes, 
CDE reports and HIRA reports. Results: Since January 2012, 17 products were 
assessed by the reimbursement authorities in both Korea and Taiwan. 12 products 
received the same reimbursement decisions from both countries, while five prod-
ucts had divergent results. Of 12 products that received the same decisions, seven 
products were first assessed and reimbursed by Korea and then also reimbursed 
in Taiwan later, while only three products were first assessed and reimbursed by 
Taiwan and later followed by Korea. The other two products were assessed at the 
same time in both countries. Of five products that received different reimburse-
ment decisions, two products were first assessed by Korea and Taiwan respectively, 
while the other product was assessed at the same time in both countries. Though 
the sample size is limited, these data suggest a possible positive influence of 
Korean HTA decisions on those in Taiwan. The average time difference between 
the Korea and Taiwan HTA assessments was 7.7 months, while Taiwan HTA assess-
ments, on average, lagged behind Korea by 2.6 months. ConClusions: In general, 
Taiwan HTA assessments lag behind Korea by 2-3 months. This may result from a 
proactive launching strategy from manufactures, as HTA decisions made in Korea 
may have a positive influence on those in Taiwan.
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objeCtives: More and more papers about pharmacoeconomics and outcome 
research were published in China. The aim of this study was to evaluate the quality 
of Chinese pharmacoeconomics study and outcome research through analyze 
papers published in the peer-reviewed literature in Chinese over the last five 
years. Methods: We conducted full-text paper searches in public databases from 
2009 to 2013 in China. A search strategy and inclusion criteria were set up to iden-
tify the articles to be included. The search identified 820 studies, of which 411 were 
included. Then papers were evaluated through a framework which was based on 
Pharmacoeconomics guideline. Results: Our results showed that a large number 
of published studies were of suboptimal quality. Most of pharmaceonomics and 
outcome research were conduct by doctors (33.6%) and pharmacists (54%) in China. 
Prospective studies (65.9%) were the most common study design, while most data 
were derived from the clinical trials; Only 8% of them included articles clearly 
stated the study perspective; More than half studies (56.2%) only computed drug 
expenditure in cost estimation; 2.2% of articles conducted discounting; 63.5% of 
studies performed the incremental analysis, however, most studies presented 
the cost-effectiveness ratios as incremental cost-effectiveness ratio; Sensitive 
analysis were reported by 71.3% of the included studies, nonetheless, the choice 
of variables for sensitivity analysis wasn’t justified; A few studies (7.3%) presented 
the transferability of the results. ConClusions: The above data signify that the 
quality of pharmacoeconomic evaluations needs improvement. There were just 
few studies which had well-designed schemes, high-qualified data and suitable 
methodology, partly owing to the doctors and pharmacists’ lack of pharmaceo-
nomics expertise and knowledge. It implied China should improve the training 
of pharmaceonomics and outcome research training in doctors and pharmacists. 
Moreover, a further study of the new technology on pharmacoeconomy should 
not be neglected.
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